GNCA Stock UPDATES Genocea Biosciences Inc. (GNCA) 9.02 10/21/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genocea Biosciences Inc. (GNCA) 9.02 $GNCA

Genocea Up on Positive GEN-003 Data for Genital Herpes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 1:57PM CDT
Genocea Biosciences, Inc. (GNCA) announced data from a phase I/IIa study on its T cell-enabled immunotherapy candidate, GEN-003.
LCI: 44.96 (+1.04), NVAX: 4.99 (-0.02), AMPE: 3.70 (-0.30), GNCA: 9.02 (+0.28)

Genocea Presents Complete Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek
Business Wire - Wed Oct 08, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies against serious infectious diseases, announced today the presentation of final data from the Phase 1/2a study of GEN-003, the company's immunotherapy candidate for treatment of genital herpes. The oral presentation, titled "Therapeutic HSV-2 Vaccine (GEN-003) Results in Durable Reduction in Genital Lesions at 1 Year ", will be given on Saturday, Oct. 11 at IDWeek 2014(TM) in Philadelphia.
GNCA: 9.02 (+0.28)

Genocea wins USD1.2m grant for malaria vaccine discovery
M2 - Wed Sep 24, 6:11AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Tuesday that it has received a USD1.2m grant for the identification of protective T cell antigens for malaria vaccines.
GNCA: 9.02 (+0.28)

Genocea Announces $1.2 Million Grant for Malaria Vaccine Discovery
Business Wire - Tue Sep 23, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of protective T cell antigens for malaria vaccines.
GNCA: 9.02 (+0.28)

Genocea to Present at the 21st Annual NewsMakers in the Biotech Industry Conference
Business Wire - Fri Sep 19, 8:00AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the BioCentury 21st Annual NewsMakers in the Biotech Industry Conference. The presentation is scheduled for Friday, September 26, 2014 at 10:30 a.m. ET at the Millennium Broadway Hotel & Conference Center in New York, NY.
GNCA: 9.02 (+0.28)

Virology Publishes Genocea HSV-2 Antigen Discovery Paper
Business Wire - Tue Sep 16, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that the peer-reviewed journal Virology has published a paper describing how Genocea used it's ATLAS(TM) platform to identify the herpes simplex virus 2 (HSV-2) antigens for its GEN-003 clinical program. The paper, titled "Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors," positively identified multiple viral antigens that are associated with naturally-induced protective CD4+ and CD8+ T cell responses, presenting possible targets for the development of new immunotherapies and prophylactic vaccines.
GNCA: 9.02 (+0.28)

Genocea reports launch of Phase 2a trial for universal pneumococcal vaccine candidate GEN-004
M2 - Fri Sep 12, 7:58AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) announced on Thursday that it has started its Phase 2a trial of its universal vaccine candidate against pneumococcus, GEN-004.
GNCA: 9.02 (+0.28)

Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate
Business Wire - Thu Sep 11, 1:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company's universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults.
GNCA: 9.02 (+0.28)

Genocea Appoints Kenneth Bate to its Board of Directors
Business Wire - Thu Sep 11, 11:30AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Kenneth Bate has joined the company's board of directors. Mr. Bate will also serve as chairman of the company's Compensation committee and a member of the Audit committee.
GNCA: 9.02 (+0.28)

Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC
Business Wire - Sat Sep 06, 3:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus (Streptococcus pneumoniae) The poster (G-291), titled "Safety and Immunogenicity of a Novel Lipidated Protein Subunit Streptococcus Pneumoniae vaccine," was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
GNCA: 9.02 (+0.28)

HSV-2 Vaccine in Development: CBCD Congratulates Genocea Biosciences (GNCA)
PRWeb - Sun Aug 17, 1:46AM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GNCA: 9.02 (+0.28)

Genocea Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported recent corporate highlights and its financial results for the second quarter ended June 30, 2014.
GNCA: 9.02 (+0.28)

Genocea to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on August 6, 2014 at 9:00 a.m. ET to discuss financial results for the quarter ended June 30, 2014. The presentation, hosted by Genocea president and chief executive officer Chip Clark and chief financial officer Jonathan Poole, will also provide an update on the company's recent progress and upcoming milestones.
GNCA: 9.02 (+0.28)

Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects
Business Wire - Tue Jul 22, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company's investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment. The data were presented at the 39th Annual International Herpesvirus Workshop, being held July 19-23, 2014 in Kobe, Japan.
GNCA: 9.02 (+0.28)

Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy
Business Wire - Mon Jul 21, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company's immunotherapy candidate against herpes simplex-type 2 (HSV-2).
GNCA: 9.02 (+0.28)

Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
SGYP: 2.85 (+0.11), BCRX: 11.37 (-0.23), OHRP: 7.33 (+0.03), GNCA: 9.02 (+0.28)

Genocea Biosciences decides not to pursue public offering due to market conditions
M2 - Thu Jul 17, 5:34AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) said on Wednesday that it has elected not to proceed with its plans to pursue its public offering of 3,400,000 shares of its common stock.
GNCA: 9.02 (+0.28)

Genocea Biosciences, Inc. Elects Not to Pursue Public Offering
Business Wire - Wed Jul 16, 10:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that, due to market conditions, it has elected not to proceed at this time with its previously announced plans to pursue an underwritten public offering of 3,400,000 shares of its common stock.
GNCA: 9.02 (+0.28)

Genocea Biosciences begins public offering of 3.4m common shares
M2 - Mon Jul 14, 8:55AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Monday the start of its public offering of 3,400,000 shares of its common stock.
GNCA: 9.02 (+0.28)

Genocea Biosciences, Inc. Commences Public Offering of Common Stock
Business Wire - Mon Jul 14, 6:30AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that it has commenced an underwritten public offering of 3,400,000 shares of its common stock. All the shares in the offering will be sold by Genocea.
GNCA: 9.02 (+0.28)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 38

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 301

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 105

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 23

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 5

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 92

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading

Top 5 Most Recently Viewed Articles

Banco Comercial Português Adresses Legal Risks of FX Mortgages

Updated Category News Views 191

Understanding Legal Risks in FX Mortgage Loans Banco Comercial Português, S.A. is proactive in addressing estimated legal risks associated with the foreign exchange (FX) mortgage loans portfolio managed by Bank Millennium, S.A. This initiative reflects the bank's commitment to stability and customer security amidst a complex financial landscape. Estimated Provisions for...

Continue Reading
Elevating Dating: MillionaireMatch's New Travel Feature

Updated Category News Views 117

Introducing the New Feature on MillionaireMatch MillionaireMatch, the renowned dating website catering to billionaires and successful individuals, has launched an exciting new feature known as 'Willing to Fly to Meet.' This update empowers users to indicate their readiness to travel distances for a potential romantic connection. By opting into this feature, individuals...

Continue Reading
Whistle Design Sparks Innovation for Coaches and Trainers

Updated Category News Views 151

So, here’s the lowdown: a new whistle design is hitting the scene, aiming to make coaches’ calls clearer amidst the chaos of overlapping games. But let’s not get lost in the novelty—this isn’t just about some fancy gadget; it’s got implications worth dissecting. First up, this invention is supposedly patent-pending. That tag usually raises eyebrows in finance...

Continue Reading
UK Imposes Sanctions on Russian Military for Chemical Warfare

Updated Category News Views 119

UK Sanctions Against Russian Military Forces The UK government has taken a bold step to address the ongoing situation in Ukraine by imposing sanctions on Russian military personnel linked to the use of chemical weapons on the battlefield. This decisive action showcases the UK's commitment to upholding international law and protecting human rights. Targeted Sanctions on...

Continue Reading
PepsiCo Prepares for Challenging Q3 Amid Pricing Pressures

Updated Category News Views 296

PepsiCo's Current Market Position PepsiCo, Inc. (NASDAQ: PEP) continues to show resilience as it navigates a complex economic environment. Recently, the company’s shares have been trading slightly higher, reflecting a degree of investor confidence amidst ongoing market challenges. Analyst Insights on Upcoming Earnings According to analyst Peter T. Galbo from BofA...

Continue Reading